Vaccination of High Risk Breast Cancer Patients Lacking Identifiable Disease With GM2-KLH Conjugate [melanoma vaccine; Progenics] Plus the Immunological Adjuvant QS21
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2010
At a glance
- Drugs Melanoma vaccine (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 17 Dec 2009 Actual end date (Nov 2001) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Nov 2005 New trial record.